Home > Browse Research > Life Sciences > Pharmaceuticals > Therapeutic Area > Oncology/Hematology

Oncology/Hematology: market research reports

Cancer is the second-leading cause of death in the United States, and the world market for cancer therapeutics is growing at a brisk double-digit pace, with revenues surpassing $40 billion this year. MarketResearch.com presents the information you need to understand the Oncology & Hematology Industries, with oncology and hematology reports that provide insight into market trends, analyses, opportunities, projections, sales, and marketing strategies.

Our hematology and oncology reports feature specifics on market share, segmentation, size, and growth in the US and global markets.

Oncology/Hematology market research reports and industry analysis

Bladder Cancer – Executive Market Summary 2013 5/20/2013 \| published by: Timely Data Resources, Inc. ... on diagnosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the cancer market, as well as sales of leading drugs and therapies are provided. \| read more...	$950.00
The World Market for Pain Management Drugs and Devices 5/20/2013 \| published by: Kalorama Information ... as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the ... \| read more...	$3,500.00
Colorectal Cancer – Executive Market Summary 2013 5/20/2013 \| published by: Timely Data Resources, Inc. ... and prognosis, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the cancer market, as well as sales of leading drugs and therapies are provided. \| read more...	$950.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players 5/15/2013 \| published by: GlobalData ... up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the ... \| read more...	$2,995.00
Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 5/15/2013 \| published by: GlobalData ... leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to ... \| read more...	$3,495.00
The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives 5/8/2013 \| published by: Kalorama Information ... selection, therapy monitoring and early detection of cancer recurrence. The market for cancer testing are comprehensively covered in Kalorama Information's Worldwide Market for Cancer Diagnostics, 5th. Edition. This report, authored by Kalorama Diagnostic Analyst Shara ... \| read more...	$4,500.00
Lymphoma Treatment Drugs Markets in China 5/1/2013 \| published by: Asia Market Information & Development Company ... trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers ... \| read more...	$2,000.00
Oropharyngeal Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer. Oropharyngeal Cancer - Pipeline Review, Half Year ... \| read more...	$2,000.00
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma ... \| read more...	$2,000.00
Metastatic Ovarian Cancer – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer ... \| read more...	$2,000.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
Soft Tissue Sarcoma – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... therapeutic development for Soft Tissue Sarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma. Soft Tissue Sarcoma ... \| read more...	$2,000.00
Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also ... \| read more...	$2,000.00
Metastatic Adenocarcinoma of The Pancreas – Pipeline Review, H1 2013 4/30/2013 \| published by: Global Markets Direct ... provides information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for ... \| read more...	$2,000.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or ... \| read more...	$4,995.00
PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 4/30/2013 \| published by: GlobalData ... Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or ... \| read more...	$4,995.00

< prev 1 2 3 4 5 6 7 8 9 10 next >